Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

被引:0
|
作者
Hayato Kawachi
Motohiro Tamiya
Akihiro Tamiya
Seigo Ishii
Katsuya Hirano
Hirotaka Matsumoto
Yasushi Fukuda
Toshihide Yokoyama
Ryota Kominami
Daichi Fujimoto
Kazutaka Hosoya
Hidekazu Suzuki
Tomonori Hirashima
Masaki Kanazu
Nobuhiko Sawa
Junji Uchida
Mitsunori Morita
Takeshi Makio
Satoshi Hara
Toru Kumagai
机构
[1] Osaka International Cancer Institute,Department of Thoracic Oncology
[2] National Hospital Organization Kinki-Chuo Chest Medical Center,Department of Internal Medicine
[3] Hyogo Prefectural Amagasaki General Medical Center,Department of Respiratory Medicine
[4] Kurashiki Central Hospital,Department of Respiratory Medicine
[5] National Hospital Organization Himeji Medical Center,Department of Respiratory Medicine
[6] Kobe City Medical Center General Hospital,Department of Respiratory Medicine
[7] Osaka Habikino Medical Center,Department of Thoracic Oncology
[8] National Hospital Organization Osaka Toneyama Medical Center,Department of Thoracic Oncology
[9] Osaka General Medical Center,Department of Respiratory Medicine
[10] Kobe City Medical Center West Hospital,Department of Respiratory Medicine
[11] Itami City Hospital,Department of Respiratory Medicine
来源
Investigational New Drugs | 2020年 / 38卷
关键词
Immune checkpoint inhibitor; Pembrolizumab; Non-small cell lung cancer; Metastatic site; Treatment outcome;
D O I
暂无
中图分类号
学科分类号
摘要
Associations between treatment outcomes of immune checkpoint inhibitors and metastatic sites in advanced non-small cell lung cancer (NSCLC) are not well known. Therefore, this multicenter retrospective study aimed to investigate the predictive factors of metastatic sites after first-line pembrolizumab treatment for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%. We retrospectively analyzed advanced NSCLC patients with a PD-L1 TPS ≥50% who underwent first-line pembrolizumab therapy at 11 institutions between February 2017 and April 2018. Clinical data collected from medical records included metastatic sites at the time of pembrolizumab treatment. Treatment outcomes of pembrolizumab were assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1. In total, 213 patients were included in the study. The median age was 71 years (range 39–91 years). Of the 213 patients, 176 (83%) were men and 172 (81%) had an Eastern Cooperative Oncology Group performance status (ECOG-PS) score of 0–1. The most common metastases were thoracic lymph node metastasis (77%), intrapulmonary metastasis (31%), bone metastasis (28%), and malignant pleural effusion (26%). On multivariate analysis, a poor ECOG-PS score (hazard ratio: 1.95, 95.0% confidence interval: 1.25–3.04; P = 0.003) and malignant pleural effusion (hazard ratio: 1.52, 95.0% confidence interval: 1.01–2.29; P = 0.043) were independent predictors of shorter progression-free survival in patients treated with pembrolizumab. For NSCLC patients with malignant pleural effusion, pembrolizumab monotherapy is not a suitable first-line treatment because of its insufficient effectiveness, even though their PD-L1 TPS was high.
引用
收藏
页码:211 / 218
页数:7
相关论文
共 50 条
  • [31] Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
    Tachibana, Yusuke
    Morimoto, Kenji
    Yamada, Tadaaki
    Kawachi, Hayato
    Tamiya, Motohiro
    Negi, Yoshiki
    Goto, Yasuhiro
    Nakao, Akira
    Shiotsu, Shinsuke
    Tanimura, Keiko
    Takeda, Takayuki
    Okada, Asuka
    Harada, Taishi
    Date, Koji
    Chihara, Yusuke
    Hasegawa, Isao
    Tamiya, Nobuyo
    Katayama, Yuki
    Nishioka, Naoya
    Iwasaku, Masahiro
    Tokuda, Shinsaku
    Kijima, Takashi
    Takayama, Koichi
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (05) : 538 - 546
  • [32] Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab
    Yamaguchi, Ou
    Kaira, Kyoichi
    Shinomiya, Shun
    Mouri, Atsuto
    Hashimoto, Kosuke
    Shiono, Ayako
    Miura, Yu
    Akagami, Tomoe
    Imai, Hisao
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    THORACIC CANCER, 2021, 12 (03) : 304 - 313
  • [33] Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
    Isla, Dolores
    Lopez-Brea, Marta
    Espinosa, Maria
    Arrabal, Natalia
    Perez-Parente, Diego
    Carcedo, David
    Bernabe-Caro, Reyes
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [34] Comparative efficacy of six programmed cell death Protein-1 inhibitors as first-line treatment for advanced non-small cell lung cancer: a multicenter retrospective cohort study
    Chen, Siyuan
    Li, Tao
    Yang, Wenyu
    Wang, Ting
    Qin, Yuhui
    Du, Zhijuan
    Li, Yanan
    Cui, Pengfei
    Hu, Yi
    Liu, Zhefeng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [35] Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
    Dolores Isla
    Marta Lopez-Brea
    María Espinosa
    Natalia Arrabal
    Diego Pérez-Parente
    David Carcedo
    Reyes Bernabé-Caro
    Cost Effectiveness and Resource Allocation, 21
  • [36] Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study
    Gumus, Mahmut
    Chen, Chieh-, I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri J. S.
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    CANCER, 2023, 129 (01) : 118 - 129
  • [37] A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL)
    Cafaro, Alessandro
    Foca, Flavia
    Nanni, Oriana
    Chiumente, Marco
    Coppola, Marina
    Baldo, Paolo
    Orzetti, Sabrina
    Enrico, Fiorenza
    Ladisa, Vito
    Lerose, Rosa
    Nardulli, Patrizia
    Maiolino, Piera
    Gradellini, Federica
    Gasbarro, Anna Rita
    Carrucciu, Gisella
    Provasi, Riccardo
    Cappelletto, Paola Cristina
    Pasqualini, Alessandra
    Vecchia, Stefano
    Veraldi, Marianna
    De Francesco, Adele Emanuela
    Crino, Lucio
    Delmonte, Angelo
    Masini, Carla
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [38] Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
    Zhang, Jie
    Wu, Di
    Zhang, Ziran
    Long, Jieran
    Tian, Guangming
    Wang, Yang
    Ma, Xiangjuan
    Chen, Xiaoling
    Han, Jindi
    Hu, Weiheng
    Dai, Ling
    Nie, Jun
    Fang, Jian
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [39] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
    Mathilde Bureau
    Thierry Chatellier
    Tanguy Perennec
    Thomas Goronflot
    Charlotte Greilsamer
    Anne-Laure Chene
    Raafet Affi
    Eric Frampas
    Jaafar Bennouna
    Elvire Pons-Tostivint
    Cancer Immunology, Immunotherapy, 2022, 71 : 1747 - 1756
  • [40] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab
    Bureau, Mathilde
    Chatellier, Thierry
    Perennec, Tanguy
    Goronflot, Thomas
    Greilsamer, Charlotte
    Chene, Anne-Laure
    Affi, Raafet
    Frampas, Eric
    Bennouna, Jaafar
    Pons-Tostivint, Elvire
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1747 - 1756